MRI Features of Hepatocellular Carcinoma Related to Biologic Behavior

Eun-Suk Cho, MD\textsuperscript{1}, Jin-Young Choi, MD\textsuperscript{2}

\textsuperscript{1}Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, Korea; \textsuperscript{2}Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul 120-752, Korea

Imaging studies including magnetic resonance imaging (MRI) play a crucial role in the diagnosis and staging of hepatocellular carcinoma (HCC). Several recent studies reveal a large number of MRI features related to the prognosis of HCC. In this review, we discuss various MRI features of HCC and their implications for the diagnosis and prognosis as imaging biomarkers. As a whole, the favorable MRI findings of HCC are small size, encapsulation, intralesional fat, high apparent diffusion coefficient (ADC) value, and smooth margins or hyperintensity on the hepatobiliary phase of gadoxetic acid–enhanced MRI. Unfavorable findings include large size, multifocality, low ADC value, non-smooth margins or hypointensity on hepatobiliary phase images. MRI findings are potential imaging biomarkers in patients with HCC.

Index terms: Hepatocellular carcinoma; Magnetic resonance imaging; Prognosis

INTRODUCTION

A clinical prognosis is an estimate of the likely course and outcome of a disease. In general, the type, location, stage, and histologic grade of the tumor are the most important factors that predict the outcome of cancer patients. Among these factors, the prognosis of solid tumors is greatly affected by tumor stage. However, in patients with hepatocellular carcinoma (HCC), prognosis assessment is complicated due to the biological heterogeneity of the disease and the lack of consensus over the best classification system (1, 2). To assess the prognosis of HCC patients, it is recommended that the staging system take into consideration tumor stage, liver function, physical status and treatment efficacy (1, 3). Traditionally, TNM or Okuda classification is used for staging HCC despite some limitations (1, 3). The Barcelona-Clinic Liver Cancer staging system links staging with a specific treatment strategy and with an estimation of life expectancy (4). Currently, there is no agreement on a worldwide recommended staging system.

Biomarkers are especially useful in cancer patients in a number of ways, including measuring the progress of disease, establishing outcome, and evaluating recurrence. Biomarkers are measurable indicators of the severity or presence of some disease state and act as surrogate endpoints (5-8). Four technological approaches can provide biomarkers such as body fluid, solid tissue samples, physiological measurements, and imaging (8). Among these, imaging biomarkers have the unique benefit in that they distinguish the exact disease focus. They are relatively non-invasive and repeatable. Imaging biomarkers can be classified in 4 ways: diagnostic, monitoring, predictive, and response biomarkers (8). Despite the advances in imaging biomarkers in the areas of diagnosis, monitoring,
and response, there are only few predictive or prognostic imaging markers, especially in patients with HCC.

Until now it is widely accepted that tumor size, multifocality, and vascular invasion are the most important prognostic factors of HCC (9-11). These variables are incorporated into various staging systems, and imaging plays a major role in the assessment of these variables. Therefore, the established roles of imaging include not only screening and surveillance of at-risk patients, but also diagnosis, staging, and prognostication of HCC (12). For these purposes, magnetic resonance imaging (MRI) is advantageous because of its high soft tissue contrast, capacity for multiple parameters, and use of various contrast agents. Furthermore, in addition to the severity of liver disease and tumor characteristics, several other features related to survival have emerged from a large number of studies. Therefore, some magnetic resonance (MR) imaging features may have prognostic, as well as the diagnostic values (Table 1). In this review, we discuss the MRI features of HCC and their implications for prognosis.

**Size and Multifocality**

The size and number of tumors, which together represent tumor burden, are important prognostic factors for HCC (9, 10); they are included in various radiological staging systems (13). As tumor size increases, HCCs tend to have a higher frequency of vascular invasion, extrahepatic metastasis and a decrease in patient survival. The availability and success of curative treatment options, such as liver resection or transplantation, depends heavily on the size and number of HCCs. Patients with one 2–5-cm HCC nodule or 2 to 3 HCC nodules measuring < 3 cm, who have no macrovascular invasion or extrahepatic metastases, have priority for transplantation (14). Liver resection for HCCs < 3 cm in size improves long-term patient survival (15). However, tumors > 3 cm have a higher incidence of microvascular invasion, especially in tumors of “nodular with extranodular growth” or “confluent multinodular type” (16-18). For patients with small HCCs, various treatment options are available, and a favorable prognosis is expected. Small HCCs measuring < 2 cm consist of 2 distinct types: 1) small HCCs with indistinct margins, which are considered “early HCC” or “HCC of vaguely nodular type” and 2) small HCCs with distinct margins, which are considered “small and progressed HCC” or “HCC of distinctly nodular type” (19). Histologically, early HCCs consist of well-differentiated tumor cells (20) invading the fibrous tissue surrounding portal tracts, which is referred to as stromal invasion (21, 22). They grow by replacing the surrounding liver parenchyma unlike the progressed HCC (23, 24). As the early HCCs spread, they do not displace or destroy the surrounding vascular structures but replace the surrounding parenchyma presenting an indistinct margin (23-25). About 80% of small and progressed HCCs are moderately differentiated, and the other 20% are both well- and moderately-differentiated (20). Although “early HCC” has the least risk of microvascular invasion, “small and progressed HCC” is thought to exhibit vascular invasion and intrahepatic metastasis (26). Therefore, small HCCs of distinctly nodular type represent progressed cancer in spite of their small size. While HCCs of distinctly nodular type frequently show a typical enhancement pattern, HCCs of vaguely nodular type tend to show an atypical enhancement pattern such as a lack of arterial hyperenhancement or venous/delayed washout (27). Early HCCs frequently show hypo- or iso-enhancement on arterial-phase imaging, due to incomplete arterial neovascularization (28), and

| Imaging Features of HCC | Diagnostic Marker | Predictive Value for Tumor Differentiation | Prognostic Marker |
|-------------------------|-------------------|------------------------------------------|-------------------|
| Size                    | No                | No                                       | Yes               |
| Multifocality           | No                | No                                       | Yes               |
| Fibrous and/or pseudocapsule | Yes              | No                                       | Yes               |
| Intratumoral fat        | Yes               | Yes                                      | Yes               |
| T1 hyperintensity       | Yes               | Yes                                      | No                |
| Mosaic appearance       | Yes               | No                                       | No                |
| Nodule-in-nodule appearance | Yes             | Yes                                      | No                |
| Corona enhancement      | Yes               | No                                       | Yes               |
| Vascular invasion       | Yes               | No                                       | Yes               |
| Signal intensity on hepatobiliary phase | No     | Yes                                      | Yes               |
| ADC value               | Yes               | Yes                                      | Yes               |

ADC = apparent diffusion coefficient, HCC = hepatocellular carcinoma
cannot be detected reliably using extracellular agents (29). However, because organic anion transporting peptide (OATP) 8 expression decreases before the sufficient arterial inflow during multistep hepatocarcinogenesis, early HCCs may appear hypointense in the hepatobiliary phase (30, 31), and some early HCCs are observed only in the hepatobiliary phase (32, 33).

More than one third of patients with HCC have multifocal hepatic nodules (34), which are defined as tumor nodules clearly separated by intervening non-neoplastic liver parenchyma (35). Multifocal tumors may represent either multiple independent HCCs arising simultaneously (multicentric HCC) or intrahepatic metastases from a primary HCC (36). Multicentric tumors may exhibit varying histological grade and other features, while all metastatic tumors of a single HCC are considered progressed lesions with advanced tumor grade. The prognosis of patients with intrahepatic metastasis from HCC tends to be worse than those with multicentric HCCs (37). Intrahepatic metastases develop by 2 different pathways. Small satellite nodules around the primary tumor are formed when tumor cells enter the portal venules that drain from the primary tumor and spread into the surrounding parenchyma (38, 39). Metastatic nodules outside the drainage area, including other segments or the contralateral lobe, develop via systemic circulation of tumor cells (40).

Fibrous Capsule and/or Pseudocapsule

The presence of a fibrous capsule is one of the characteristic findings of nodular, progressed HCC (41), and is found in 24–90% of Asians and 12–42% of non-Asians with HCC (11). Since cirrhotic or dysplastic nodules (DNs) usually do not develop a fibrous capsule, the presence of a capsule is an important finding in HCC (23). Although some investigators have found that capsule appearance does not increase the diagnostic accuracy for HCC because it usually coincides with other hallmark imaging features, other investigators assert that capsule appearance is valuable, as it permits diagnosis of HCC without a definite washout appearance (14, 42). Capsule presence is regarded as a major diagnostic criterion for HCC, along with arterial hyperenhancement, according to the liver imaging reporting and data system (43), and Organ Procurement and Transplantation Network.

Histologically, the fibrous capsule consists of an inner layer rich in pure, fibrous tissue and an outer layer containing portal venules (or sinusoids) and newly formed bile ducts (41, 44). The fibrous capsule is a common pathological feature of progressed HCC, but not of early HCC, DNs, or regenerative nodules (23). The fibrous capsule shows a thin rim of hypointensity on T1-weighted images and a hypointense or hyperintense rim on T2-weighted images (Fig. 1). On dynamic MRI, the enhancing rim shown...
on portal venous or delayed phase images (45) are from the retention of the extracellular contrast agent within the prominent peritumoral sinusoids and/or fibrosis (45, 46). On hepatobiliary contrast agent-enhanced MRI, the relatively high enhancement of the background liver parenchyma may obscure capsular enhancement during the late dynamic or transitional phase. Some HCCs do not have a true fibrous capsule even though the MRI may show a hypointense rim on T1-weighted and T2-weighted imaging (45): an enhancing rim on delayed phase images can mimic the fibrous capsule. Such a false-positive fibrous capsule, i.e., a pseudocapsule, on MRI represents prominent histopathological hepatic sinusoids and/or peritumoral fibrosis (41, 45).

Hepatocellular carcinoma with a fibrous capsule is considered a favorable prognostic factor, as it is associated with more effective transarterial chemoembolization (TACE) and lower recurrence rates after resection or ablation (47-49). This may be due to the barrier effect of the fibrous capsule that inhibits HCC dissemination (50). HCCs with a pseudocapsule may also confer a favorable prognosis because they exhibit similar behavior in terms of vascular invasion and tumor grade compared to a HCC with a true fibrous capsule (41, 45). It is important to note that encapsulated HCC does not have a better prognosis than early-stage or small HCC, because the presence of a capsule indicates progressed HCC (12, 51). In other words, HCCs with intact capsules have a better prognosis than HCCs of similar grade and size without capsules or with disrupted capsules (41, 45, 51).

Intratumoral Fat in HCC

Hepatocellular carcinomas sometimes contain an internal fat component (11), which is reportedly found in up to 19.6% of HCCs on light microscopy and in up to 10% of HCCs on MRI (44, 52). In patients with cirrhosis, the presence of intraleral fat raises concern for malignancy or premalignant lesions (53). Though intraleral fat is very rare in hepatic malignancies except for HCC, the detection of fat may help to exclude intrahepatic cholangiocarcinoma (29). Despite potential benefits, the diagnostic value of intraleral fat has not yet been determined. Intraleral fat is shown to be noncontributory in radiological diagnosis of HCC, as the presence of fat coincides with other more discriminatory imaging features, such as arterial hyperenhancement or delayed washout (54, 55). Intraleral fat can be detected by identification of a signal drop on opposed-phase images, compared to in-phase, T1-weighted, chemical-shift gradient-recalled-echo MR images (Fig. 2) (43, 55-57).

Intraleral fatty change or fatty metamorphosis occasionally occurs during hepatocarcinogenesis (53), and diffuse fatty metamorphosis is considered as one of the...
characteristics of early-stage HCC (52). Fatty change is most frequently found in HCCs with a diameter of approximately 1.5 cm, and the prevalence decreases incrementally with tumor size and histologic grade. This feature is uncommon in HCCs > 3 cm in diameter and/or in moderately differentiated HCCs (25). Approximately 6% of moderately differentiated HCCs reportedly have fatty change, while no poorly differentiated HCCs exhibit this feature (52). In early-stage HCCs, the blood source gradually shifts from the vessels of the portal tracts to the newly formed non-triadal arteries. At this transitional stage, the lack of blood supply and increased cellular density may cause transient hypoxia, which may lead to intratumoral fatty metamorphosis (19, 52). However, the molecular mechanism of fatty metamorphosis by hypoxia in HCCs is not fully understood.

Patients with fat-containing HCC may have a better clinical outcome than patients without fat-containing HCCs due to longer time to tumor progression and decreased risk of metastasis. This may be due to the fact that intraslesional fat is characteristic of early and well-differentiated HCC, not of progressed HCC (58). The prognosis of progressed HCC with intraslesional fat has not been established.

**T1 Hyperintensity**

Hepatocellular carcinomas may have variable signal intensity on T1-weighted images. Although most hepatic lesions are hypointense relative to liver parenchyma on T1-weighted images, some HCCs show T1 hyperintensity (59-62). T1 hyperintensity can be attributed to the presence of T1 shortening substances such as fat, copper, highly-concentrated proteins, glycogen and hemorrhages within the nodules (63).

Hepatocellular carcinomas are more commonly hypointense on T1-weighted images. In a previous report, T1 signal intensity of HCCs was hypointense in 65% of cases, isointense in 23%, and hyperintense in 12% (64). Unenhanced T1-weighted imaging plays a minor role in the diagnosis of HCC because HCCs and non-malignant hepatic lesions have various and overlapping T1 signal intensity (65, 66). However, the signal intensity on T1-weighted images may be associated with histologic grade and clinical outcome (59, 61). It has been previously reported that 64–66% of HCCs of Edmondson-Steiner grade I or with well-differentiated histology show hyperintensity on T1-weighted imaging (Fig. 3) (59, 61). However, the proportion of HCC nodules with hyperintensity on T1-weighted imaging gradually decreases as the histological differentiation grade progresses (61). Therefore, HCCs with T1 hyperintensity tend to have better tumor histologic grade, while HCCs with T1 hypointensity tend to be more poorly differentiated (59, 61). Besides, T1 hyperintense HCCs without T2 hyperintensity or arterial hypervascularity usually follow a benign clinical course (67).

---

**Fig. 3.** 71-year-old man with HCC showing T1 hyperintensity.

A. Unenhanced fat-saturated T1-weighted three-dimensional gradient echo image with fat suppression (TR/TE/FA = 2.5 ms/0.9 ms/11°) shows hyperintense mass (arrow) in segment 4. B. Mass is barely visible on fat-suppressed fast spin echo T2-weighted imaging due to isointense signal (arrow). FA = flip angle, HCC = hepatocellular carcinoma, TE = echo time, TR = repetition time
**Nodule-in-Nodule Appearance**

Nodule-in-nodule appearance represents the presence of a small nodule within a larger nodule (43). This imaging appearance corresponds to the nodule-in-nodule growth pattern on histology (68) and suggests a focus of progressed HCC within a well-differentiated HCC or DN (19). Histologically, the inner nodule is composed of less differentiated cancer tissue, containing less fat and/or iron, while the parent nodule is a well-differentiated HCC or DN rich in fat and/or iron (69, 70). When less-differentiated cancerous tissues within the well-differentiated nodules proliferate in an expansive fashion, a ‘nodule-in-nodule’ appearance is frequently seen. Thus, a nodule-in-nodule appearance could be interpreted as a morphologic marker of the progression of dedifferentiation of the tumor (19, 68).

The inner nodule, corresponding to a developing and distinctly nodular-type HCC, shows T2 hyperintensity, T1 hypointensity, and arterial enhancement on dynamic imaging (Fig. 4) (28, 71). On the other hand, the preexisting parent nodule, corresponding to either a DN or early HCC tissue, demonstrates T2 hypointensity, T1 hyperintensity, and hypovascularity on dynamic imaging (11, 72, 73). The inner HCC nodule has radiological and pathologic features typical of progressed HCC with the potential for rapid growth and doubling time (74). However, consideration of the nodule-in-nodule appearance of HCC as a prognostic factor is not established (29).

**Corona Enhancement**

Corona enhancement, one of the characteristics of hypervascular HCC, is described as a transient zone or rim of enhancement around a hypervascular HCC in the late arterial phase seen in either CT hepatic arteriography (75) or multiaxial phase dynamic MRI (Fig. 5) (63, 76). Since corona enhancement is a very unusual finding other than HCC, it is one of the most reliable features for distinguishing HCC from other hypervascular tumors or pseudolesions such as arterioportal shunts (77). Because corona enhancement is transient, it is hard to recognize on routine CT or MRI. Corona enhancement is seen only in the perfusion phase of dynamic study, such as the arterial or early portal venous phases and not the equilibrium phase (76). This is different from capsular enhancement, which is mainly seen as an enhancing rim in the delayed phase images (76).

In addition to the ancillary imaging features, the importance of corona enhancement is related to blood drainage in HCC. The drainage vessels of HCC change during multistep carcinogenesis (78). As the tumor cells proliferate more rapidly, they first invade the intranodular hepatic veins; however, tumor blood drainage via intranodular and perinodular hepatic veins disappears early, as perinodular hepatic veins are collapsed by tumor compression. Then, venous blood from tumors begins to drain into surrounding hepatic sinusoids and portal veins (75, 78). In HCCs with a fibrous capsule, perinodular hepatic sinusoids collapse,
and the fibrous capsule interrupts the connection between intranodular and extranodular sinusoids. Consequently, tumor venous blood drains into the surrounding liver parenchyma via portal venules within the capsule, which can be seen as thick corona enhancement on imaging (40, 75, 78). Thus, corona enhancement may provide prognostic information. Local recurrence is frequently observed at the area of corona enhancement, as this corresponds to the initial drainage pathway of the tumor (40). The area of corona enhancement is the first site of intrahepatic metastasis of HCC, and daughter nodules are commonly found in this area. Therefore, resection or ablation of tumors should include the regions of corona enhancement to avoid tumor recurrence (40).

Vascular Invasion by HCC

Vascular invasion is more common in HCCs that are larger or of higher histologic grade (38, 79-83). Tumor cells more frequently involve the portal venous system than hepatic veins (64, 82, 84). Vascular invasion is divided into macro- and microvascular invasion, depending on the level of involved vascular structures (14). Both types of vascular invasion are related to poor prognosis because they provide the route for tumor cells to access the portal or systemic circulation, which can result in intrahepatic or systemic metastases. Thus, HCCs with vascular invasion have frequent multifocality and a higher recurrence rate after hepatic resection, ablation therapy, or liver transplantation (85, 86). Therefore, surgical resection or liver transplantation is usually contraindicated in HCCs with macrovascular invasion (87).

It is difficult to preoperatively predict microvascular invasion with imaging studies as it occurs at a microscopic level (88). Microvascular invasion of HCC is reportedly not predictable using morphologic and enhancement features of MRI, such as T1 and T2 signal intensity, margins, presence of capsule or pseudocapsule, wedge-shaped peritumoral enhancement, or quantitative tumor enhancement (18, 76). However, several tumor characteristics on MRI have been suggested as markers for risk of microvascular invasion. Morphologically, tumors with more than 3 foci and a tumor size > 3 cm exhibiting gross patterns of “nodular with extranodular growth”, “confluent multinodular type”, or “infiltrative type” are reported to be closely related to microvascular invasion (16-18). Therefore, multiple tumors or tumors > 3 cm with non-smooth margins on MRI are likely to have microvascular invasion. Additionally, HCCs of < 2 cm, especially those of distinct nodular type, may exhibit microvascular invasion (32). These tumors usually show a typical dynamic enhancement pattern and hyperintensity on T2-weighted and diffusion-weighted images (32). Some studies have suggested that large or irregular and distorted corona enhancement in HCC may predict microvascular invasion (76, 89-91). However, this finding is not been validated by other studies. Peritumoral hypointensity and

---

Fig. 5. 66-year-old man with HCC showing corona enhancement.

A, B. T1-weighted three-dimensional GRE image with fat suppression (TR/TE/FA = 4.5 ms/2.1 ms/15°) in (A) early and (B) late hepatic arterial phase after administration of gadolinium-based contrast agent shows hyper-enhancing mass (arrow) in segment 6. Notice irregular circumferential enhancement (arrow) in liver parenchyma around mass in late hepatic arterial phase. C. Enhancement of perilesional parenchyma fades in portal venous phase. Transient enhancement of perilesional parenchyma is known as corona enhancement. Note capsular appearance of mass (arrow). FA = flip angle, GRE = gradient echo, HCC = hepatocellular carcinoma, TE = echo time, TR = repetition time.
non-smooth tumor margins on the hepatobiliary phase of gadoxetic acid-enhanced MRI may also be indicative factors of microvascular invasion (Fig. 6) (17, 91). In areas of peritumoral hypointensity of the liver parenchyma, expression of OATPs and canalicular transporter multidrug resistance-associated protein 2 receptors decrease, probably because of hemodynamic alteration related to tumor obstruction of minute portal veins (17). The tumor margin may be non-smooth if the tumor is infiltrative or with a minute budding portion at its periphery (91).

Organic Anion Transporter Polypeptide Expression and Signal Intensity on Hepatobiliary Phase Imaging

Gadoxetic acid and gadobenate dimeglumine are 2 hepatobiliary contrast agents, currently available in clinical practice (12). They behave like extracellular agents after injection, are taken up by functioning hepatocytes and excreted into the biliary system. OATP 8 (also known as OATP1B1/3) is thought to be responsible for uptake of hepatobiliary contrast agents by hepatocytes (92, 93). Thus, nodules with low or no OATP expression do not take up hepatobiliary agents and appear hypointense in the hepatobiliary phase, while nodules with preserved or elevated OATP 8 expression take up the agents and tend to be isointense or hyperintense.

The expression of these transporters decreases during hepatocarcinogenesis. Expression levels are high in regenerating nodules and low-grade DNAs and are lower in many high-grade DNAs, early HCCs, and progressed HCCs (92, 94). On the hepatobiliary phase of gadoxetic acid-enhanced MRI, HCCs are usually hypointense from the lack of gadoxetic acid uptake due to down regulation of OATP 8 expression (95, 96). Studies have shown that the degree of tumor enhancement in the hepatobiliary phase after injection of gadoxetic acid inversely correlates with histologic grades (92, 97). Poorly-differentiated tumors tend to show lower signal intensity, as compared to well-differentiated or moderately-differentiated ones. Inverse correlation has been associated to the gradual decline in OATP expression seen during hepatocarcinogenesis (92, 94). This suggests that quantitative analysis of tumor enhancement in the hepatobiliary phase may predict histologic and prognostic features (92). However, other researchers show that the degree of tumor enhancement does not correspond with tumor grades (95, 98) or only correlates in a subset of patients with preserved liver function (99).

Some HCCs show hyperintensity on hepatobiliary phase due to increased uptake of hepatobiliary contrast media (Fig. 7) (100-103). The overexpression of OATP 8 in some HCCs may be due to genomic alteration during hepatocarcinogenesis (92). The prevalence of these hyperintense HCCs on hepatobiliary phase varies from 5 to 12% (100-102). Most patients have well- or moderately-differentiated tumors, but poor differentiation is observed rarely (92, 95, 97, 100, 102, 103). Thus, the hyperintensity of HCCs on hepatobiliary phase may not be dependent on histologic differentiation of the tumor, but rather on the degree of OATP 8 expression or other potential genomic alterations (94, 97, 104).

Hyperintense HCCs on hepatobiliary phase may indicate a favorable clinical outcome in patients (95) since these tumors have infrequent microvascular invasion and have a longer interval of recurrence, as compared with hypointense HCCs (95, 102, 104, 105). Moreover, hyperintense HCCs most commonly appear as expanding gross-type, not
Infiltrative or diffuse-type, which are prone to poor prognosis (95). Patients with iso- to hyperintense HCCs on hepatobiliary phase tend to have lower levels of prognostic serum tumor markers (α-fetoprotein, protein induced by vitamin K absence or antagonist-II [PIVKA-II]) (104, 106, 107). Hyperintense HCCs on hepatobiliary phase are more common in older patients, suggesting that they grow more slowly (95, 98, 100, 103).

**Correlation of MR Imaging and Immunohistochemical Markers**

Prognosis is not easy to determine in patients with HCC due to the heterogeneous nature of the tumors and the lack of appropriate biomarkers. Despite the advancement of molecular medicine, there are no well-established biomarkers to predict prognosis of HCC. Currently used tumor markers in HCC, such as alpha-fetoprotein or PIVKA-II, have limited sensitivity and specificity; however, some immunohistochemical markers have the potential to be used for prognosis and treatment stratification.

Hepatocellular carcinomas with biliary phenotypic markers such keratin 7 and keratin 19 (K19) may be more aggressive and have a worse prognosis (108, 109). Some HCCs expressing progenitor cell markers, such as epithelial cell adhesion molecule (EpCAM) and K19 have...
aggressive clinical outcomes due to a higher recurrence rate after resection or liver transplantation, resistance to chemoradiation therapy, and a higher rate of metastases (24, 108-117). It is reported that HCCs expressing EpCAM or K19 show different radiologic features on MRI, as compared with HCCs lacking these markers (Fig. 8) (110). Gross multinodular confluent- or infiltrative-type tumors that are associated with an unfavorable prognosis are more common (110). A progressive or persistent enhancement pattern on dynamic study, similar to the enhancement pattern of cholangiocarcinoma, is more frequently seen in HCCs expressing progenitor cell markers (110). On gadoxetic acid-enhanced MRI, K19 expression is inversely correlated with tumor enhancement of HCC on hepatobiliary phase. Therefore, tumor enhancement on hepatobiliary phase is lower in K19-positive HCCs than in K19-negative HCCs (110, 118).

Diffusion-Weighted Imaging

One of the characteristic radiologic features of many malignant tumors is elevated signal intensity on diffusion-weighted imaging, caused by a reduced apparent diffusion coefficient (ADC) of water in the tumor microenvironment (Fig. 9) (119). The mechanism of reduced ADC is not completely understood, but may reflect greater diffusion hindrance and reduced mobility of water molecules due to decreased extracellular space and increased tortuosity of the extracellular space matrix (120-123). Most but not all (124) studies show that the addition of diffusion-weighted imaging to MRI improves the detection of HCC (125-127) and intrahepatic HCC metastases (128). The ADC value may provide information on tumor behavior. Since cellularity and the nuclear-to-cytoplasmic (N/C) ratio are major features used to determine histologic grading, high-grade tumors have densely-packed cells and a high N/C ratio in general. Densely-packed tumor cells can inhibit effective motion of water molecules and can restrict diffusion. Thus, the ADC value and the appearance on diffusion-weighted imaging likely reflect tumor cellularity and microenvironment.

Some studies suggest that measuring the ADC value can predict tumor histopathologic grade (129-133), microvascular invasion (88), the presence of progenitor cell markers (110), and early recurrence after resection (132). However, these correlations are not always consistent, and some studies show no significant correlation between ADC and histopathologic grade of HCCs due to the large overlap of ADC among different histopathologic grades (134). Because the ADC value and diffusion-weighted signal intensity ratios particularly depend on techniques, magnetic field strength, and MRI scanners, diffusion-weight-based prediction thresholds may not yet be generalized.
Diffusion-weighted imaging is used to monitor efficacy of treatment using TACE and target therapy (135-140). Some studies report that the ADC value of HCCs increase after TACE (136-138), and a high baseline ADC value could predict poor response to TACE (135, 140). In HCCs treated with an antiangiogenic agent (sorafenib), the ADC value may temporarily decrease in the early phase of treatment and increase again in long-term follow-up (> 3 months) (139). However, ADC values vary widely and may not contribute to the accurate diagnosis of tumor necrosis by any cut-off levels. Increased ADC may be caused not only by tumor necrosis, but also by perilesional inflammation and arterial reperfusion after TACE (141).

CONCLUSION

MRI can not only be used for non-invasive diagnosis and staging, but also for predicting tumor biology as an imaging biomarker in patients with HCC. Favorable findings of HCCs on MRI include small size, presence of fibrous capsule/ pseudocapsule, intrasexual fat, high ADC value, and smooth margins or hyperintensity on hepatobiliary phase images, while unfavorable findings of HCCs include large size, multifocality, low ADC value, non-smooth margins or hypointensity on hepatobiliary phase images.

REFERENCES

1. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005;7:35-41
2. Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol 2014;20:4141-4150
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-524
4. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:225-235
5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95
6. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:846-856
7. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81:104-107
8. Mishra A, Verma M. Cancer biomarkers: are we ready for the prime time? Cancers (Basel) 2010;2:190-208
9. Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int 2006;26:680-687
10. Chen WT, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, et al. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. Eur J Surg Oncol 2004;30:414-420
11. Khatri G, Merrick L, Miller FH. MR imaging of hepatocellular carcinoma. Magn Reson Imaging Clin N Am 2010;18:421-450, x
12. Choi JY, Lee JM, Siriltin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014;272:635-654
13. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000;31:840-845
14. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:262-278
15. Giuliani F, Ardito F, Pinna AD, Sarno G, Giulini SM, Ercolani G, et al. Liver resection for hepatocellular carcinoma ≤3 cm: results of an Italian multicenter study on 588 patients. J Am Coll Surg 2012;215:244-254
16. Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M. Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl 2011;17 Suppl 2:S72-S80
17. Kim KA, Kim MJ, Jeon HM, Kim KS, Choi JS, Ahn SH, et al. Prediction of microvascular invasion of hepatocellular carcinoma: usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images. J Magn Reson Imaging 2012;35:629-634
18. Chandarana H, Robinson E, Hajdu CH, Drozhnin L, Babb JS, Taouli B. Microvascular invasion in hepatocellular carcinoma: is it predictable with pretransplant MRI? AJR Am J Roentgenol 2011;196:1083-1089
19. Efremidis SC, Hytiroglou P, Matsui O. Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma: correlation with differentiation. Liver 1999;19:12-18
20. Kondo F, Kondo Y, Nagato Y, Tomizawa M, Wada K. Interstitial tumour cell invasion in small hepatocellular carcinoma. Evaluation in microscopic and low magnification views. J Gastroenterol Hepatol 1994;9:604-612
21. Kojiro M. Histopathology of liver cancers. Best Pract Res Clin Gastroenterol 2005;19:39-62
22. Roncalli M, Park YN, Di Tommaso L. Histopathological
classification of hepatocellular carcinoma. *Dig Liver Dis* 2010;42 Suppl 3:S228-S234.

25. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. *Hepatology* 2009;49:658-664.

26. Park YN. Update on precursor and early lesions of hepatocellular carcinomas. *Arch Pathol Lab Med* 2011;135:704-715.

27. ChoiYS, Rhee H, Choi JY, Chung YE, ParkYN, Kim KW, et al. Histological characteristics of small hepatocellular carcinomas showing atypical enhancement patterns on gadoxetic acid-enhanced MR imaging. *J Magn Reson Imaging* 2013;37:1384-1391.

28. Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. *Radiology*2011;261:834-844.

29. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracelluleral agents, hepatobiliary agents, and ancillary imaging features. *Radiology* 2014;273:30-50.

30. Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. *Eur Radiol* 2010;20:2405-2413.

31. Bartolozzi C, Battaglia V, Bargellini I, Bozzi E, Campani D, Pollina LE, et al. Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. *Abdom Imaging* 2013;38:290-296.

32. Kim MJ, Lee M, Choi JY, Park YN. Imaging features of small hepatocellular carcinomas with microvascular invasion on gadoxetic acid-enhanced MR imaging. *Eur J Radiol* 2012;81:2507-2512.

33. Ooka Y, Kanai F, Okabe S, Ueda T, Shimofusa R, Ogasawara S, et al. Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. *Magn Reson Imaging* 2013;31:748-754.

34. Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. *Cancer* 2002;95:1931-1937.

35. Theise ND, Curado MP, Franceschi S, Hytirolou P, Kudo M, ParkYN, et al. *Hepatocellular carcinoma*. In: Bosman FT, Carneiro F, Huban RH, Theise ND, eds. *WHO Classification of Tumors of the Digestive System*, 4th ed. Lyon: International Agency for Research on Cancer, 2010:205-216.

36. Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. *Carcinogenesis* 2008;29:1299-1305.

37. Wang J, Li Q, Sun Y, Zheng H, Cui Y, Li H, et al. Clinicopathologic features between multicentric occurrence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. *Surg Oncol* 2009;18:25-30.

38. Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojirio M. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. *Hepatol Res* 2003;26:142-147.

39. Itoh K, Nishimura K, Togashi K, Fujisawa I, Noma S, Minami S, et al. Hepatocellular carcinoma: MR imaging. *Radiology* 1987;164:21-25.

40. Sakon M, Nagano H, Nakamori S, Dono K, Umeshita K, Murakami T, et al. Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy: analysis based on tumor hemodynamics. *Arch Surg* 2002;137:94-99.

41. Ishigami K, Yoshimitsu K, Nishihara Y, Irie H, Asayama Y, Tajima T, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. *Radiology* 2009;250:435-443.

42. American College of Radiology. Liver Imaging Reporting and Data System version 2013.1. Web site. http://www.acr.org/Quality-Safety/Resources/LIRADS/. Accessed July 19, 2013.

43. Macarini L, Milillo P, Cascavilla A, Scalo G, Stoppino L, Vinci R, et al. MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers. *Radiol Med* 2009;114:1267-1282.

44. Kadoya M, Matsui O, Takashima T, Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. *Radiology* 1992;183:819-825.

45. Grazioli L, Olivetti L, Fugazzola C, Benetti A, Stanga C, Dettori E, et al. The pseudocapsule in hepatocellular carcinoma: correlation between dynamic MR imaging and pathology. *Eur Radiol* 1999;9:62-67.

46. Ito Y, Ohtomo K, Kubo T, Yamauchi T, Minami M, Yashiro N, et al. CT of hepatic masses: significance of prolonged and delayed enhancement. *AJR Am J Roentgenol* 1986;146:729-733.

47. Ng IO, Lai EC, Ng MM, Fan ST. Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases. *Cancer* 1992;70:45-49.

48. Lee CS, Hwang LY, Beasley RP, Hsu HC, Lee HS, Lin TY. Prognostic significance of histologic findings in resected small hepatocellular carcinoma. *Acta Chir Scand* 1988;154:199-203.

49. Lai EC, Ng IO, Ng MM, Lok AS, Tam PC, Fan ST, et al. Long-term results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathologic features. *Hepatology* 1990;11:815-818.

50. Lim JH, Choi D, Park CK, Lee WJ, Lim HK. Encapsulated hepatocellular carcinoma: CT-pathologic correlations. *Eur Radiol* 2006;16:2326-2333.

51. Iuchi T, Aishima S, Sanefuji K, Fujita N, Sugimachi K, Gion T, et al. Both fibrous capsule formation and extracapsular penetration are powerful predictors of poor survival in human hepatocellular carcinoma: a histological assessment of 365 patients in Japan. *Ann Surg Oncol* 2009;16:2539-
MRI Features of HCC Related to Biologic Behavior

2546

52. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000;33:282-289

53. Yu JS, Chung JJ, Kim JH, Kim KW. Fat-containing nodules in the cirrhotic liver: chemical shift MRI features and clinical implications. AJR Am J Roentgenol 2007;188:1009-1016

54. Kim TK, Lee KH, Jang HJ, Haider MA, Jacks LM, Menezes RJ, et al. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 2011;259:730-738

55. Rimola J, Fornes A, Tremosini S, Reig M, Vilana R, Bianchi L, et al. Non-invasive diagnosis of hepatocellular carcinoma ≤2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol 2012;56:1317-1323

56. Martin J, Sentis M, Zidan A, Donoso L, Puig J, Falcó J, et al. Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging. Radiology 1995;195:125-130

57. Mitchell DG, Palazzo J, Hann HW, Rifkin MD, Burk DL Jr, Rubin R. Hepatocellular tumors with high signal on T1-weighted MR images: chemical shift MR imaging and histologic correlation. J Comput Assist Tomogr 1991;15:762-769

58. Siripongsakun S, Lee JK, Raman SS, Tong MJ, Sayre J, Lu DS. MRI detection of intratumoral fat in hepatocellular carcinoma: potential biomarker for a more favorable prognosis. AJR Am J Roentgenol 2012;199:1018-1025

59. Ebara M, Fukuda H, Kojima Y, Morimoto N, Yoshikawa M, Sugiyama N, et al. Small hepatocellular carcinoma: relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma. Radiology 1999;210:81-88

60. Shinmura R, Matsui O, Kobayashi S, Terayama N, Sanada J, Ueda K, et al. Cirrhotic nodules: association between MR imaging signal intensity and intranodal blood supply. Radiology 2005;237:512-519

61. Enomoto S, Tamai H, Shingaki N, Mori Y, Moribata K, Shiraki T, et al. Assessment of hepatocellular carcinomas using conventional magnetic resonance imaging correlated with histological differentiation and a serum marker of poor prognosis. Hepatol Int 2011;5:730-737

62. Earls JP, Theise ND, Weinreb JC, DeCorato DR, Krinsky GA, Rofsky NM, et al. Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. Radiology 1996;201:207-214

63. Ito K, Fujita T, Shimizu A, Koike S, Sasaki K, Matsunaga N, et al. Multiterial phase dynamic MRI of small early enhancing hepatic lesions in cirrhosis or chronic hepatitis: differentiating between hypervascular hepatocellular carcinomas and pseudolesions. AJR Am J Roentgenol 2004;183:699-705

64. Kelekis NL, Semelka RC, Worawattanakul S, de Lange EE, Ascher SM, Ahn IO, et al. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images. AJR Am J Roentgenol 1998;170:1005-1013

65. Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Arai K, Gabata T, et al. Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology 1989;173:123-126

66. Zech CJ, Reiser MF, Herrmann KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis 2009;27:114-124

67. Yu JS, Lee JH, Park MS, Kim KW. Hyperintense nodules on non-enhanced T1-weighted gradient-echo magnetic resonance imaging of cirrhotic liver: fate and clinical implications. J Magn Reson Imaging 2006;24:630-636

68. Kojiro M. 'Nodule-in-nodule' appearance in hepatocellular carcinoma: its significance as a morphologic marker of dedifferentiation. Intervirology 2004;47:179-183

69. Terada T, Kadoya M, Nakanuma Y, Matsui O. Iron-accumulating adenomatous hyperplastic nodule with malignant foci in the cirrhotic liver. Histopathologic, quantitative iron, and magnetic resonance imaging in vitro studies. Cancer 1990;65:1994-2000

70. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005;25:133-142

71. Winter TC 3rd, Takayasu K, Muramatsu Y, Furukawa H, Wakao F, Koga H, et al. Early advanced hepatocellular carcinoma: evaluation of CT and MR appearance with pathologic correlation. Radiology 1994;192:379-387

72. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009;44 Suppl 19:112-118

73. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 2008;28:747-769

74. Sadek AG, Mitchell DG, Siegelman ES, Outwater EK, Matteucci T, Hann HW. Early hepatocellular carcinoma that develops within macroregenerative nodules: growth rate depicted at serial MR imaging. Radiology 1995;195:753-756

75. Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Nakashima Y, Ikeno H, et al. Detection of corona enhancement of hypervascular hepatocellular carcinoma by C-arm dual-phase cone-beam CT during hepatic arteriography. Cardiovasc Intervent Radiol 2011;34:81-86

76. Kim H, Park MS, Choi JY, Park YN, Kim MJ, Kim KS, et al. Can microvessel invasion of hepatocellular carcinoma be predicted by pre-operative MRI? Eur Radiol 2009;19:1744-1751

77. Kanematsu M, Kondo H, Goshima S, Tsuge Y, Watanabe H. Magnetic resonance imaging of hepatocellular carcinoma. Oncology 2008;75 Suppl 1:65-71
78. Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y. Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography--radiologic-pathologic correlation. *Radiology* 2009;252:605-614.

79. Kanai T, Hirohashi S, Upton MP, Noguchi M, Kishi K, Makuuchi M, et al. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. *Cancer* 1987;60:810-819.

80. Hui AM, Takayama T, Sano K, Kubota K, Akahane M, Ohtomo K, et al. Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. *J Hepatol* 2000;33:975-979.

81. Albacete RA, Matthews MJ, Saini N. Portal vein thromboses in malignant hepatoma. *Ann Intern Med* 1967;67:337-348.

82. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. *Cancer* 1954;7:462-503.

83. Freeny PC. Portal vein tumor thrombus: demonstration by computed tomographic arteriography. *J Comput Assist Tomogr* 1980;4:263-264.

84. Stevens WR, Johnson CD, Stephens DH, Battps KP. CT findings in hepatocellular carcinoma: correlation of tumor characteristics with causative factors, tumor size, and histologic tumor grade. *Radiology* 1994;191:531-537.

85. Shin WY, Suh KS, Lee HW, Kim J, Kim T, Yi NJ, et al. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. *Liver Transpl* 2010;16:678-684.

86. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. *J Am Coll Surg* 2003;197:753-758.

87. Llovet JM, Fuster J, Bruix J; Barcelona-Clínic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. *Liver Transpl* 2004;10(2 Suppl 1):S115-S120.

88. Suh YJ, Kim MJ, Choi JY, Park MS, Kim KW. Preoperative prediction of the microvascular invasion of hepatocellular carcinoma with diffusion-weighted imaging. *Liver Transpl* 2012;18:1171-1178.

89. Miyata R, Tanimoto A, Wakabayashi G, Shimazu M, Nakatsuka S, Mukai M, et al. Accuracy of preoperative prediction of microinvasion of portal vein in hepatocellular carcinoma using superparamagnetic iron oxide-enhanced magnetic resonance imaging and computed tomography during hepatic angiography. *J Gastroenterol* 2006;41:987-995.

90. Nishie A, Yoshimitsu K, Asayama Y, Irie H, Tajima T, Hirakawa M, et al. Radiologic detectability of minute portal venous invasion in hepatocellular carcinoma. *AJR Am J Roentgenol* 2008;190:81-87.

91. Ariizumi S, Kitagawa K, Kotera Y, Takahashi Y, Katagiri S, Kuwatsuru R, et al. A non-smooth tumor margin in the hepatobiliary phase of gadoteric acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging predicts microscopic portal vein invasion, intrahepatic metastasis, and early recurrence after hepatectomy in patients with hepatocellular carcinoma. *J Hepatobiliary Pancreat Sci* 2011;18:575-585.

92. Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. *Eur Radiol* 2011;21:2056-2066.

93. Tsuda N, Harada K, Matsui O. Effect of change in transporter expression on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging during hepatocarcinogenesis in rats. *J Gastroenterol Hepatol* 2011;26:568-576.

94. Vavrivka SR, Jung D, Fried M, Grützner U, Meier PJ, Kulak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. *J Hepatol* 2004;40:212-218.

95. Kim JY, Kim MJ, Kim KA, Jeong HT, Park YN. Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features. *Eur J Radiol* 2012;81:3877-3882.

96. Frieriks BB, Loddenkemper C, Huppertz A, Valdeig S, Stroux A, Seja M, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. *AJR Am J Roentgenol* 2009;193:1053-1060.

97. Tsunoyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. *Radiology* 2010;255:824-833.

98. Asayama Y, Tajima T, Nishie A, Ishigami K, Kakihara D, Nakayama T, et al. Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production. *Eur J Radiol* 2011;80:e243-e248.

99. Kim HY, Choi JY, Kim CW, Bae SH, Yoon SK, Lee YJ, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis. *Liver Transpl* 2012;18:850-857.

100. Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. *J Hepatobiliary Pancreat Sci* 2009;16:793-798.

101. Suh YJ, Kim MJ, Choi JY, Park YN, Park MS, Kim KW. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. *AJR Am J Roentgenol* 2011;197:W44-W52.

102. Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Koda W, et al. Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. *Radiology* 2012;265:780-789.
MRI Features of HCC Related to Biologic Behavior

103. Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging—correlation with molecular transporters and histopathologic features. Radiology 2010;256:817-826

104. Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 2013;267:776-786

105. Vosuri F, Golferi R, Fiorentino M, Capizzi E, Renzulli M, Pinna AD, et al. OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation. Virchows Arch 2011;459:141-146

106. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognostic of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989;64:1700-1707

107. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 1994;73:2464-2471

108. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004;3:73-81

109. Durnez A, Verslype C, Nevens F, Feyer J, Aerts R, Pirenne J, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006;49:138-151

110. Jeong HT, Kim MJ, Kim YE, Park YN, Choi GH, Choi JS. MRI features of hepatocellular carcinoma expressing progenitor cell markers. Liver Int 2012;32:430-440

111. Yamashita T, Forgue M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-1461

112. Yamashita T, Ji J, Budhu A, Forgue M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012-1024

113. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556

114. Lee JS, Heo J, Libbrecht L, Chu JS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416

115. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003;94:851-857

116. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol 1996;149:1167-1175

117. Fan ST. Selection of HCC patients for liver transplantation: the Milan criteria, Hangzhou criteria and beyond. Hepatobiliary Pancreat Dis Int 2008;7:233-234

118. Choi JY, Kim MJ, Park YN, Lee JM, Yoo SK, Rha SY, et al. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics. AJR Am J Roentgenol 2011;197:399-405

119. Maier SE, Sun Y, Mulkern RV. Diffusion imaging of brain tumors. NMR Biomed 2010;23:849-864

120. White NS, Dale AM. Distinct effects of nuclear volume fraction and cell diameter on high b-value diffusion MRI contrast in tumours. Magn Reson Med 2014;72:1435-1443

121. Sykova E, Nicholson C. Diffusion in brain extracellular space. Physiol Rev 2008;88:1277-1340

122. Pfeuffer J, Flögel U, Dreher W, Leibritz D. Restricted diffusion and exchange of intracellular water: theoretical modelling and diffusion time dependence of 1H NMR measurements on perfused glial cells. NMR Biomed 1998;11:19-31

123. Le Bihan D. Molecular diffusion, tissue microdynamics and microstructure. NMR Biomed 1995;8:375-386

124. Kim YK, Kim CS, Han YM, Lee YH. Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial? Clin Radiol 2011;66:489-496

125. Xu PJ, Yan FH, Wang JH, Lin J, Ji Y. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis. J Magn Reson Imaging 2009;29:341-349

126. Vandecaveye V, De Keyzer F, Verslype C, Op de Beeck K, Komuta M, Topal B, et al. Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol 2009;19:2456-2466

127. Park MJ, Kim YK, Lee MW, Lee WJ, Kim YS, Kim SH, et al. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 2012;264:761-770

128. Yu JS, Chung JJ, Kim JH, Cho ES, Kim DJ, Ahn JH, et al. Detection of small intrahepatic metastases of hepatocellular carcinomas using diffusion-weighted imaging: comparison with conventional dynamic MRI. Magn Reson Imaging 2011;29:985-992

129. An C, Park MS, Jeon HM, Kim YE, Chung WS, Chung YE, et al. Prediction of the histopathological grade of hepatocellular carcinoma using qualitative diffusion-weighted, dynamic, and hepatobiliary phase MRI. Eur Radiol 2012;22:1701-1708

130. Heo SH, Jeong YY, Shin SS, Kim JW, Lim HS, Lee JH, et al. Apparent diffusion coefficient value of diffusion-weighted imaging for hepatocellular carcinoma: correlation with the
histologic differentiation and the expression of vascular endothelial growth factor. Korean J Radiol 2010;11:295-303

131. Muhi A, Ichikawa T, Motosugi U, Sano K, Matsuda M, Kitamura T, et al. High-b-value diffusion-weighted MR imaging of hepatocellular lesions: estimation of grade of malignancy of hepatocellular carcinoma. J Magn Reson Imaging 2009;30:1005-1011

132. Nakanishi M, Chuma M, Hige S, Omatsu T, Yokoo H, Nakanishi K, et al. Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol 2012;19:1302-1309

133. Nishie A, Tajima T, Asayama Y, Ishigami K, Kakihara D, Nakayama T, et al. Diagnostic performance of apparent diffusion coefficient for predicting histological grade of hepatocellular carcinoma. Eur J Radiol 2011;80:e29-e33

134. Nasu K, Kuroki Y, Tsukamoto T, Nakajima H, Mori K, Minami M. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol 2009;193:438-444

135. Hayano K, Fuentes-Orrego JM, Sahani DV. New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol 2014;20:3059-3068

136. Kamel IR, Bluemke DA, Ramsey D, Abusedera M, Torbenson M, Eng J, et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 2003;181:708-710

137. Goshima S, Kanematsu M, Kondo H, Yokoyama R, Tsuge Y, Shiratori Y, et al. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 2008;27:834-839

138. Chen CY, Li CW, Kuo YT, Jaw TS, Wu DK, Jao JC, et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants—initial experience. Radiology 2006;239:448-456

139. Schraml C, Schwenzer NF, Martirosian P, Bitzer M, Lauer U, Claussen CD, et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009;193:W301-W307

140. Yuan Z, Ye XD, Dong S, Xu LC, Xu XY, Liu SY, et al. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol 2010;75:e9-e14

141. Kele PG, van der Jagt EJ. Diffusion weighted imaging in the liver. World J Gastroenterol 2010;16:1567-1576